310 related articles for article (PubMed ID: 24398856)
1. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
2. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
3. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
[TBL] [Abstract][Full Text] [Related]
5. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
6. A multi-targeted approach to treating bone metastases.
Camacho DF; Pienta KJ
Cancer Metastasis Rev; 2014 Sep; 33(2-3):545-53. PubMed ID: 24390423
[TBL] [Abstract][Full Text] [Related]
7. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
Zhang X
Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
[TBL] [Abstract][Full Text] [Related]
8. Targeting bone physiology for the treatment of metastatic prostate cancer.
Autio KA; Morris MJ
Clin Adv Hematol Oncol; 2013 Mar; 11(3):134-43. PubMed ID: 23598981
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
Turner CJ; Edwards CM
Curr Osteoporos Rep; 2016 Oct; 14(5):170-7. PubMed ID: 27566487
[TBL] [Abstract][Full Text] [Related]
11. Bone metabolism and new targets for intervention.
Akduman B; Crawford ED
Curr Urol Rep; 2007 May; 8(3):233-8. PubMed ID: 17459273
[TBL] [Abstract][Full Text] [Related]
12. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
13. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in bone-targeted therapies of metastatic prostate cancer.
Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
[TBL] [Abstract][Full Text] [Related]
17. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer.
Msaouel P; Galeas JN; Boiles AR; Ruiz RR; Koutsilieris M
Curr Drug Targets; 2016; 17(3):276-89. PubMed ID: 25892311
[TBL] [Abstract][Full Text] [Related]
19. Skeletal-related events in prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
[No Abstract] [Full Text] [Related]
20. The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.
Suominen MI; Wilson T; Käkönen SM; Scholz A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31405099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
